检索结果-南通市图书馆

Biomedical and Environmental Sciences 2023年第6期36卷 501-509页

作者： XU Cai Hong QIU Ying Peng HE Zi Long HU Dong Mei YUE Xiao CHEN Zhong Dan XU Yuan Yuan ZHAO Yan Lin National Center for Tuberculosis Control and Prevention China CDCBeijing 100226China China National Health Development Research Center Beijing 100226China The University of Sheffield S102TNSheffieldThe United Kingdom The Central South University Changsha 410083HunanChina World Health Organization Representative Office for China Beijing 100600China

Objective This study aims to estimate the cost-effectiveness of the combined chemotherapy regimen containing Bedaquiline(BR)and the conventional treatment regimen(CR,not containing Bedaquiline)for the treatment of adults with multidrug-resistant tuberculosis(MDR-TB)in *** A combination of a decision tree and a Markov model was developed to estimate the cost and effects of MDR patients in BR and CR within ten *** model parameter data were synthesized from the literature,the national TB surveillance information system,and consultation with *** incremental cost-effectiveness ratio(ICER)of BR *** was *** BR(***)had a higher sputum culture conversion rate and cure rate and prevented many premature deaths(decreased by 12.8%),thereby obtaining more quality-adjusted life years(QALYs)(increased by 2.31 years).The per capita cost in BR was as high as 138,000 yuan,roughly double that of *** ICER for BR was 33,700 yuan/QALY,which was lower than China's 1×per capita Gross Domestic Product(GDP)in 2020(72,400 yuan).Conclusion BR is shown to be cost *** the unit price of Bedaquiline reaches or falls below57.21 yuan per unit,BR is expected to be the dominant strategy in China over CR.

关键词： Bedaquiline cost-effectiveness Multidrug-resistant tuberculosis China

cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2017年第5期16卷 493-498页

作者： Rong-Ce Zhao Jing Zhou Yong-Gang Wei Fei Liu Ke-Fei Chen Qiu Li Bo Li Department of Liver Surgery and Liver Transplantation Center West China Hospital Sichuan University Chengdu 610041 China Department of Medical Oncology Cancer Center State Key Laboratory of BiotherapyWest China Hospital Sichuan University Chengdu 610041 China

BACKGROUND: Transcatheter arterial chemoembolization(TACE) and TACE in combination with sorafenib(TACEsorafenib) have shown a significant survival benefit for the treatment of unresectable hepatocellular carcinoma(HCC). Adopting either as a first-line therapy carries major cost and resource implications. The objective of this study was to estimate the relative cost-effectiveness of TACE against TACE-sorafenib for unresectable HCC using a decision analytic ***: A Markov cohort model was developed to compare TACE and TACE-sorafenib. Transition probabilities and utilities were obtained from systematic literature reviews, and costs were obtained from West China Hospital, Sichuan University, China. Survival benefits were reported in quality-adjusted life-years(QALYs). The incremental cost-effectiveness ratio(ICER) was calculated. Sensitive analysis was performed by varying potentially modifiable parameters of the ***: The base-case analysis showed that TACE cost $26 951 and yielded survival of 0.71 QALYs, and TACE-sorafenib cost $44 542 and yielded survival of 1.02 QALYs in the entire treatment. The ICER of TACE-sorafenib versus TACE was $56 745 per QALY gained, which was above threshold for cost-effectiveness in China. Sensitivity analysis revealed that the major driver of ICER was the cost post TACE-sorafenib therapy with stable ***: TACE is a more cost-effective strategy than TACE-sorafenib for the treatment of unresectable HCC.

关键词： hepatocellular carcinoma transcatheter arterial chemoembolization TACE in combination with sorafenib cost-effectiveness

cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第12期22卷 3460-3470页

作者： Ming-Jeng Kuo Hsiu-Hsi Chen Chi-Ling Chen Jean Ching-Yuan Fann Sam Li-Sheng Chen Sherry Yueh-Hsia Chiu Yu-Min Lin Chao-Sheng Liao Hung-Chuen Chang Yueh-Shih Lin Amy Ming-Fang Yen Department of Hepatogastroenterology Tainan Municipal Hospital Tainan 701 Taiwan Graduate Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University Taipei 100 Taiwan Graduate Institute of Clinical Medicine College of Medicine and Graduate Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University Taipei 100 Taiwan Department of Health Industry Management School of Healthcare Management Kainan University Taoyuan 338 Taiwan School of Oral Hygiene College of Oral Medicine Taipei Medical University Taipei 110 Taiwan Department and Graduate Institute of Health Care Management Chang Gung University Taoyuan 333 Taiwan Division of Gastroenterology Department of Internal Medicine Shin-Kong Wu Ho-Su Memorial Hospital Taipei 111 Taiwan angder Health Clinics Taipei 111 Taiwan

AIM: To assess the cost-effectiveness of two populationbased hepatocellular carcinoma(HCC) screening programs, two-stage biomarker-ultrasound method and mass screening using abdominal ultrasonography(AUS).METHODS: In this study, we applied a Markov decision model with a societal perspective and a lifetime horizon for the general population-based cohorts in an area with high HCC incidence, such as Taiwan. The accuracy of biomarkers and ultrasonography was estimated from published meta-analyses. The costs of surveillance, diagnosis, and treatment were based on a combination of published literature, Medicare payments, and medical expenditure at the National Taiwan University Hospital. The main outcome measure was cost per lifeyear gained with a 3% annual discount rate. RESULTS: The results show that the mass screening using AUS was associated with an incremental costeffectiveness ratio of USD39825 per life-year gained, whereas two-stage screening was associated with an incremental cost-effectiveness ratio of USD49733 per life-year gained, as compared with no screening. Screening programs with an initial screening age of 50 years old and biennial screening interval were the most cost-effective. These findings were sensitive to the costs of screening tools and the specificity of biomarker ***: Mass screening using AUS is more cost effective than two-stage biomarker-ultrasound screening. The most optimal strategy is an initial screening age at 50 years old with a 2-year inter-screening interval.

关键词： Two-stage biomarker-ultrasound screening One-stage abdominal ultrasonography screening Markov model cost-effectiveness Sensitivity analysis Age

cost-effectiveness of lutetium(^177Lu)oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2020年第20期8卷 4793-4806页

作者： Jayne Palmer Oscar R Leeuwenkamp Ossian Health Economics and Communications Basel 4051Switzerland Advanced Accelerator Applications Geneva 1204Switzerland

BACKGROUND Gastroenteropancreatic neuroendocrine tumors(GEP-NETs)represent a relatively rare and heterogenous group of *** available treatment options for patients with progressive GEP-NETs include lutetium(177 Lu)oxodotreotide(177 LuDotatate)and everolimus[as well as sunitinib for patients with pancreatic NETs(P-NETs)].AIM To perform a health economic analysis to determine the cost-effectiveness of 177 LuDotatate compared with everolimus in patients with unresectable or metastatic midgut-NETs or P-NETs in both Sweden and *** Simulations were performed using a three-state partitioned survival model and analyses were performed separately for patients with midgut-NETs and *** input data were sourced from an indirect comparison that utilized survival data from clinical trials of 177 Lu-Dotatate and *** analyses were performed from the healthcare payer perspective over a time horizon of 20 *** Sweden,future costs and clinical outcomes were discounted at 3%per *** Norway,a discount rate of 4%per annum was *** For Sweden,improved survival outcomes and higher lifetime costs with 177 LuDotatate resulted in an incremental cost-effectiveness ratio(ICER)of SEK 391194 per quality-adjusted life year(QALY)gained for midgut NETs and SEK 16764 per QALY gained for P-NETs for 177 Lu-Dotatate compared with *** Norway,the corresponding ICERs were NOK 244444 per QALY gained and NOK 106451 per QALY gained,***-way sensitivity analyses revealed that the results were most sensitive to changes in drug acquisition costs and health state utility *** In both Sweden and Norway,from a healthcare provider perspective,177 LuDotatate is likely to be considered cost-effective relative to everolimus for the treatment of patients with unresectable or metastatic,progressive midgut-NETs or P-NETs.

关键词： cost cost-effectiveness Neuroendocrine tumors 177Lu-Dotatate Sweden Norway

cost-effectiveness analysis of colon cancer treatments from MOSIAC and No.16968 trials

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第47期20卷 17976-17984页

作者： Feng Wen Ke Yao Ze-Dong Du Xiao-Feng He Peng-Fei Zhang Rui-Lei Tang Qiu Li Department of Medical Oncology Cancer CenterState Key Laboratory of BiotherapyWest China HospitalSichuan University Department of Biostatistics West China School of Public HealthSichuan University Department of Oncology 363 Hospital Department of Medical Oncology First People’s Hospital of Longquanyi District

AIM: To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on MOSAIC and No. 16968 trails from Chinese cost-effectiveness perspective. METHODS: A decision-analytic Markov model was developed to compare the FOLFOX4 and XELOX regimens based MOSAIC and No. 16968 trial. Five states were included in our Markov model: well (state 1), minor toxicity (state 2), major toxicity (state 3), quitting adjuvant chemotherapy (state 4), and death due to adjuvant chemotherapy (state 5). Transitions among the 5 states were assumed to be Markovian. costs were calculated from the perspective of the Chinese health-care payer. The utility data were taken from published studies. Sensitivity analyses were used to explore the impact of uncertainty factors in this cost-effectiveness analysis. RESULTS: Total direct costs of FOLFOX4 and XELOX per patient were $ 19884.96 +/- 4280.30 and $ 18113.25 +/- 3122.20, respectively. The total fees related to adverse events per patient during the entire treatment were $ 204.75 +/- 16.80 for the XELOX group, and $ 873.72 +/- 27.60 for the FOLFOX4 group, and the costs for travel and absenteeism per patient were $ 18495.00 for the XELOX group and $ 21,352.68 for the FOLFOX4 group. The base-case analysis showed that FOLFOX4 was estimated to produce an additional 0.06 in quality adjusted life years (QALYs) at an additional cost of $ 3950.47 when compared to the XELOX regimen over the model time horizon. The cost per QALY gained was $ 8047.30 in the XELOX group, which was $ 900.98 less than in the FOLFOX4 group ($ 8948.28). The one way sensitivity analysis demonstrated that the utility for the well state and minor toxicity state greatly influenced the incremental cost-effectiveness ratio of FOLFOX4. CONCLUSION: In term of cost-comparison, XELOX is expected to dominate FOLFOX4 regimes; Therefore, XELOX provides a more cost-effective adjuvant chemotherapy for colon cancer patients in China. c 2014 Baishideng Publishing Group Inc. All rights res

关键词： cost-effectiveness Adjuvant chemotherapy Colon cancer FOLFOX XELOX

cost-effectiveness analysis of the integrated control strategy for schistosomiasis japonica in a lake region of China: a case study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2021年第3期10卷 109-110页

作者： Ling-Ling Wu He-Hua Hu Xia Zhang Xiao-Nong Zhou Tie-Wu Jia Can Wang Zhong Hon Jing Xu Nation al Institute of Parasitic Diseases Chinese Center for Disease Control and PreventionChinese Center for Tropical Diseases ResearchNHC Key Laboratory of Parasite and Vector BiologyWHO Collaborating Centre for Tropical DiseasesNational Center for International Research On Tropical DiseasesShanghai 200025China 不详

Background:Schistosomiasis japonica remains an important public health concern due to its potential to cause severe outcomes and Iong-term *** integrated control strategy implemented in the Peoples' Republic of China has been shown to be effective to control or interrupt the transmission of *** objective of this study is to estimate the disease burden of schistosomiasis and assess the cost-effectiveness of the integrated control strategy focused on different major interventions at three stages for schistosomiasis control in a lake setting,to provide reference for policy making or planning.

关键词： Schistosomiasis Integrated control cost-effectiveness Disability-adjusted life years China

cost-effectiveness in Clostridium difficile treatment decision-making

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2015年第11期3卷 935-941页

作者： Mark JC Nuijten Josbert J Keller Caroline E Visser Ken Redekop Eric Claassen Peter Speelman Marja H Pronk Ars Accessus Medica HAGA Teaching Hospital Clinical Microbiologist AMC iMTA and BMG EUR EUR AMC Europe-ExPro

AIM: To develop a framework for the clinical and health economic assessment for management of Clostridium difficile infection(CDI).METHODS: CDI has vast economic consequences emphasizing the need for innovative and cost effective solutions, which were aim of this study. A guidance model was developed for coverage decisions and guideline development in CDI. The model included pharmacotherapy with oral metronidazole or oral vancomycin, which is the mainstay for pharmacological treatment of CDI and is recommended by most treatment ***: A design for a patient-based cost-effectiveness model was developed, which can be used to estimate the cost-effectiveness of current and future treatment strategies in CDI. Patient-based outcomes were extrapolated to the population by including factors like, e.g., person-to-person transmission, isolation precautions and closing and cleaning wards of hospitals. CONCLUSION: The proposed framework for a population-based CDI model may be used for clinical and health economic assessments of CDI guidelines and coverage decisions for emerging treatments for CDI.

关键词： Clostridium difficile infection Guidance cost-effectiveness Model Standardisation Decision making

cost-effectiveness of lung cancer screening by low-dose CT in China:a micro-simulation study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of the National Cancer Center 2022年第1期2卷 18-24页

作者： Yihui Du Yanju Li Grigory Sidorenkov Rozemarijn Vliegenthart Marjolein A.Heuvelmans Monique D.Dorrius Harry J.M.Groen Shiyuan Liu Li Fan Zhaoxiang Ye Marcel J.W.Greuter Geertruida H.de Bock Department of Epidemiology University Medical Center GroningenUniversity of GroningenGroningenNetherlands Department of Radiology Tianjin’s Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyNational Clinical Research Centre for CancerTianjin Medical University Cancer Institute and HospitalTianjinChina Department of Radiology University Medical Center GroningenUniversity of GroningenGroningenNetherlands Department of Pulmonary Diseases University Medical Center GroningenUniversity of GroningenGroningenNetherlands Department of Radiology Shanghai Changzheng Hospitalthe Second Military Medical UniversityShanghaiChina

Background:The effectiveness of lung cancer screening with low-dose computed tomography(LDCT)has been *** current study evaluates the cost-effectiveness of lung cancer screening with LDCT in a general population in ***:A previously validated micro-simulation model was used to simulate a cohort of men and women on a lifetime horizon in the presence and absence of LDCT *** modeling data were collected from numerous national and international *** screening scenarios included different combinations of screening intervals and start and stop *** costs(valued in Chinese Yuan,CNY;1 USD=6.8976 CNY,1 EUR=7.8755 CNY in 2020),life-years gained(LYG)and mortality reduction due to screening were also *** costs and life-years were discounted by 3%.All results were scaled to 1,000 *** average cost-effectiveness ratio(ACER)was calculated.A willingness-to-pay threshold of CNY 217.3k/LYG was considered.A healthcare system perspective was ***:Compared to no screening,lung cancer screening by LDCT in a general Chinese population yielded 21.0-36.7 LYG in men and 9.2-16.6 LYG in women across the *** men,biennial LDCT screening yielded an ACER of CNY 171.4k-306.3k/LYG relative to no *** screening performed between 55 and 75 years of age was optimal at the defined threshold;it resulted in CNY 174.6k/LYG and a lung cancer mortality reduction of 9.1%,and this scenario had a 75%probability of being *** women,the ACER ranged from CNY 364.2k to 1193.3k/***:In China,lung cancer screening with LDCT in the general population including never smokers could be cost-effective for men with 75%probability,but not for *** optimal strategy for men would be performing biennial screening between 55 and 75 years of age.

关键词： cost-effectiveness Low-dose computed tomography Lung neoplasm Mass screening Microsimulation model General population

cost-effectiveness of patient specific vs conventional instrumentation for total knee arthroplasty:A systematic review and meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Orthopedics 2023年第6期14卷 458-470页

作者： Isobel M Dorling Lars Geenen Marion J L F Heymans Jasper Most Bert Boonen Martijn G M Schotanus Department of Orthopaedic Surgery and Traumatology Zuyderland Medical CenterSittard-Geleen 6162 BGLimburgNetherlands Zuyderland Academy Zuyderland Medical CenterSittard-Geleen 6155 NHLimburgNetherlands School of Care and Public Health Research Institute(CAPHRI) Faculty of HealthMedicine and Life SciencesMaastricht 6229 ERLimburgNetherlands Department of Orthopaedic Surgery and Traumatology Maastricht University Medical CenterMaastricht 6229 HXLimburgNetherlands

BACKGROUND Over the past years,patient specific instrumentation(PSI)for total knee arthroplasty(TKA)has been implemented and routinely *** clear answer has been given on its associated cost and cost-effectiveness when compared to conventional instrumentation(CI)for *** To compare the cost and cost-effectiveness of PSI TKA compared to CI *** A literature search was performed in healthcare,economical healthcare,and medical databases(MEDLINE,EMBASE,CINAHL,Web of Science,Cochrane Library,EconLit).It was conducted in April 2021 and again in January *** literature included randomised controlled trials,retrospective studies,prospective studies,observational studies,and case control *** studies were assessed on methodological *** outcomes included incremental cost-effectiveness ratio,quality-adjusted life years,total costs,imaging costs,production costs,sterilization associated costs,surgery duration costs and readmission rate *** eligible studies were assessed for risk of ***-analysis was performed for outcomes with sufficient *** Thirty-two studies were included into the systematic *** were included in the metaanalysis.3994 PSI TKAs and 13267 CI TKAs were included in the sample *** methodological quality of the included studies,based on Consensus on Health Economic Criteria-scores and risk of bias,ranged from average to *** TKA costs less than CI TKA when considering mean operating room time and its associated costs and tray sterilization per patient *** TKA costs more compared to CI TKA when considering imaging and production *** total costs per patient case,PSI TKA is more expensive in comparison to CI ***-analysis comparing total costs for PSI TKA,and CI TKA showed a significant higher cost for PSI *** cost for PSI and CI TKA can differ when considering distinct aspects of their *** costs per patient case are increased for PSI TKA whe

关键词： Total knee arthroplasty Patient specific instrumentation Instrumentation for total knee arthroplasty cost-effectiveness Systematic review

A cost-effectiveness assessment of the operational parameters of central HVAC systems during pandemics

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Building Simulation 2023年第5期16卷 667-682页

作者： Yufan Chang Zhengtao Ai Jinjun Ye Guochuan Ma Department of Building Environment and Energy College of Civil EngineeringHunan UniversityChangshaHunanChina National Center for International Research Collaboration in Building Safety and Environment Hunan UniversityChangshaHunanChina China Southwest Architectural Design and Research Institute ChengduSichuanChina

The present study develops a cost-effectiveness assessment model to analyze the performance of major operational parameters of central HVAC systems in terms of airborne transmission risk,energy consumption,and medical and social cost.A typical multi-zone building model with a central HVAC system is built numerically,and the effect of outdoor air(OA)ratio(from 30%to 100%)and filtration level(MERV 13,MERV 16,and HEPA)are assessed under the conditions of five climate zones in *** with the baseline case with 30%OA and MERV 13 filtration,the airborne transmission risk in zones without infector is negligibly reduced with the increase in OA ratio and the upgrade of filtration level,owing to their slight modification on the equivalent ventilation rate of virus-free ***,depending on climate zone,a 10%increase in OA ratio results in 12.5%-78.6%and 0.1%-8.6%increase in heating and cooling energy consumption,respectively,while an upgrade of filtration level to MERV 16 and HEPA results in an increase of 0.08%-0.2%and 1.4%-2.6%,***,when compared to the use of 100%OA ratio and HEPA filtration,the application of 30%or 40%OA ratio and MERV 13 filtration would save annually an energy and facility related cost of$29.4 billion in China,though giving an increase of approximately$0.1 billion on medical and social cost from the increased number of confirmed *** study provides basic method and information for the formulation of cost-effective operational strategies of HVAC systems coping with the airborne transmission,especially in resource-limited regions.

关键词： outdoor air ratio filtration level airborne transmission risk energy consumption cost-effectiveness